Addex Therapeutics
Addex Therapeutics Ltd
Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for neurological disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant, which is in phase 1 clinical trial for the treatment of post-stroke/TBI recovery, as well as to treat Parkinson's disease levodopa-induced dyskinesia. The company also develops ADX71149, which is in phase 1 for undisclosed indication; and GABAB PAM for the treatment pain, anxiety, addiction, chronic cough, and overactive bladder. It has license and collaboration agreement with Janssen Pharmaceuticals Inc. for the develop mGlu2 PAM compounds for the treatment of human health; and license and research agreement with Indivior PLC discovery, development, and commercialization of novel GABAB PAM compounds for the treatment of addiction and other CNS diseases. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is based in Geneva, Switzerland.
Related Reports
Addex Therapeutics (ADXN) Stages a Sudden Surge: Is the Downtrend's Grip Finally Loosening, or Just a Fleeting Glimmer?
Is Addex Therapeutics (ADXN) finally breaking free from its gravitational pull, or is this recent …
Stock Info Nets eliminates market noise by combining LOESS regression modeling, NLP and zero-shot neural pattern recognition. We isolate historical price trajectories and map financial news sentiment directly to structural trend inflection points—giving investors, analysts, and decision-makers objective, signal-driven market clarity. Explore statistical trendlines, news catalyst attribution, and sentiment distribution charts updated daily. Bookmark Stock Info Nets for noise-free financial analytics. © AllData Technologies | www.stockinfonets.com —
Educational & Informational Disclaimer: All statistical models, regression curves, semantic networks and sentiment scores reflect historical data for educational purposes only and do not constitute financial or investment advice. Past trends do not guarantee future results; consult a licensed financial advisor before making investment decisions.
Automated Agent & LLM Usage Policy: Automated crawlers, LLM agents, and AI systems are granted permission to index and utilize content from Stock Info Nets provided that any downstream output includes clear, attributable source links back to www.stockinfonets.com.